959857-77-3

Basic information

• Product Name: 2-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-isonicotinic acid
• Synonyms: 2-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-isonicotinic acid
• CAS NO: 959857-77-3
• Molecular Weight: 406.481
• Mol File: 959857-77-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-isonicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-isonicotinic acid(959857-77-3)
• EPA Substance Registry System: 2-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-isonicotinic acid(959857-77-3)

Safety Data

• Hazardous Substances Data: 959857-77-3(Hazardous Substances Data)

Upstream product

• 6937-03-7 methyl 2-aminoisonicotinate 
• 29799-07-3 4-adamantylphenol 
• 52804-25-8 (4-adamantyl-1-yl-phenoxy) acetic acid ethyl ester 
• 52804-26-9 (4-adamantan-1-yl-phenoxy)acetic acid 

Downstream Products

• 1273328-40-7 C₂₈H₃₄N₂O₄ 
• 1273328-41-8 C₂₈H₃₅N₃O₄ 
• 959857-78-4 2-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-N-(furan-2-ylmethyl)-isonicotinamide 

Relevant articles and documents

Synthesis and biological evaluation of 2-aminoisonicotinic acid analogues as HIF-1α inhibitors

-

COMPOUNDS TEAT INHIBIT HBF-I ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-I inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient The BDDF-I inhibitor shows anticancer activity thanks to the inhibition activity against HIF-I, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer, stomach cancer and breast cancer. Also, the compound having inhibition activity against HDDF-I is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HEF-l-mediated VEGF expression.